oCEM: Automatic detection and analysis of overlapping co-expressed gene modules

Quang-Huy Nguyen¹, and Duc-Hau Le^{1,2*}

¹Department of Computational Biomedicine, Vingroup Big Data Institute, Hanoi, Vietnam.

²College of Engineering and Computer Science, VinUniversity, Hanoi, Vietnam.

* corresponding author: Email: hauldhut@gmail.com; Tel: (84)912324564

Keywords: identification of modules; analysis of modules; co-expression; clinical feature association; gene expression

ABSTRACT

When it comes to the co-expressed gene module detection, its typical challenges consist of overlap between identified modules and local co-expression in a subset of biological samples. Recent studies have reported that the decomposition methods are the most appropriate for solving these challenges. In this study, we represent an R tool, termed overlapping co-expressed gene module (oCEM), which possesses those methods with a wholly automatic analysis framework to help non-technical users to easily perform complicated statistical analyses and then gain robust results. We also develop a novel auxiliary statistical approach to select the optimal number of principal components using a permutation procedure. Two example datasets are used, related to human breast cancer and mouse metabolic syndrome, to enable the illustration of the straightforward use of the tool. Computational experiment results show that oCEM outperforms state-of-the-art techniques in the ability to additionally detect biologically relevant modules. The R scripts used in the study, including all information on the tool and its usage are made publicly available at <https://github.com/huynghuyen250896/oCEM>.

INTRODUCTION

The introduction of genome-wide gene expression profiling technologies observed so far has turned the biological interpretation of large gene expression compendia using module detection methods to be a crucial pillar [1-3]. Here, a module itself is a set of genes which are similarly functioned and jointly expressed. Co-expressed modules do not only help to globally and objectively interpret gene expression data [4, 5], but it is also used to discover regulatory relationships between putative target genes and transcription factors [6-8]. Also, it is useful to study the origin [9] and development [10] of complex diseases caused by many factors.

The nature of module detection is the use of unsupervised clustering approaches and algorithms. Those methods are advanced undoubtedly, but the selection of a certain clustering method for sample- and gene-clustering tasks is separate, in which the latter task is often more complicated. Indeed, users should predetermine the following limitations before applying clustering methods to gene expression. Firstly, not all of clustering methods have the ability to tackle the problem of overlap between modules. Whereas clustering patients into biologically distinct subgroups is our ultimate goal, the way to group genes into functional modules need to be more careful since genes often do not work alone; e.g, previous studies have reported that at least five genes work in concert [11] and that their interaction is associated with multiple pathways [12]. Secondly, clustering methods often ignore local co-expression effects which only appear in a subset of all biological samples and instead are interested in co-expression among all samples. This results in loss of meaningful information due to highly context-specific transcriptional regulation [13]. Thirdly, clustering potentially misses the regulatory relationships between genes. As the interpretation of the target expression change is based partly on the change in transcription factor expression [14], this information included may help to improve the ability of module identification. Among existing clustering methods, decomposition methods [15] and biclustering [16] are said to possibly handle the first two restrictions, whereas the last restriction may be solved well by direct network inference [14] and iterative network inference [17]. These obviously affect the selection of which clustering method in the context of gene expression; however, it is rarely examined sufficiently, leading to a typical example is the tool weighted gene co-expression network analysis (WGCNA) [18] with a hierarchical agglomerative clustering [19].

Wouter Saelens *et al* [20] have conducted a holistic comparison of module detection methods for gene expression data and realized that the decomposition methods, including independent component analysis (ICA) [21-23], principal component analysis (PCA) [24], and independent principal component analysis (IPCA) [25], are the best. In this study, we have proposed an R tool, named oCEM, which integrates these methods in the hope that it could be a potential alternative to rectify the limitations above. In particular, we develop a state-of-the-art statistical method, called *optimizeCOM*, to specify the optimal number of components in advance required by them. Then, the function *overlapCEM* available in oCEM helps to implement the module detection and analysis in an automatic manner. These help non-technical users to easily perform complicated statistical analyses and gain robust results in a surprisingly rapid way. We have also demonstrated a better performance of oCEM with other high-tech methods.

MATERIAL AND METHODS

Overview of oCEM

Automatic framework of oCEM

Figure 1 shows the automatic framework for module detection and analysis included in oCEM. Gene expression matrix first suffered from the two pre-processing steps as excluding outlier individuals and normalization prior to being input of oCEM. The result of normalization was the distribution of each gene expression was centered and standardized across samples. The user now put the data to oCEM, and it printed automatically out co-expressed gene modules (A module was determined from a particular component by using one of the optional post-processing steps), corresponding hub-genes in each module, and analysis result of associations between each module and each clinical feature of choice (e.g., tumor stages, glycemic index, weight,...). Note that oCEM decomposed the expression matrix into the product of two or more sub-matrices by only using one of the two decomposition methods, including ICA (the *fastICA* algorithm) and IPCA (the *ipca* algorithm). oCEM did not include PCA because of the following reasons: (i) PCA assumes that gene expression follows a Gaussian distribution; however, many recent studies have demonstrated that microarray gene expression measurements follow instead a non-Gaussian distribution [26-29], (ii) The idea behind PCA is to decompose a big matrix into the product of several sub-matrices, and then retain the first few components which have maximum amount of variance. Mathematically, this helps to do dimension reduction, noise reduction, but the highest variance may be inappropriate to the biological reality [30, 31].

Since the output of the decomposition methods generally consisted of two parts, the components for genes and the components for samples, we, in this study, distinguished the two by the term of signatures and patterns, respectively (Supplementary Methods and FigureS1). When it came to the first matrix product (vertical rectangle in FigureS1), oCEM described the characteristic of different signatures by, between them, a set of genes of which the overlap was allowed. In contrast, for the second matrix product (horizontal rectangle in FigureS1), oCEM characterized each component by its expression patterns in biological samples.

Figure 1. Automatic analysis framework of oCEM. Gene expression data first underwent the two pre-processing steps: removal of outlier samples and normalization. Then, the user could refer to the recommendation of oCEM regarding which decomposition method should be selected and how many component numbers were optimal by using the function *optimizeCOM*. Next, the processed data were inputted into the function *overlapCEM*, rendering co-expressed gene modules (i.e., Signatures with their own kurtosis ≥ 3) and Patterns. Kurtosis statistically describes the “tailedness” of the distribution relative to a normal distribution. Finally, corresponding hub-genes in each module and the association between each module and each clinical feature of choice were identified.

***optimizeCOM* algorithm**

As the user used oCEM to investigate co-expressed modules, the first step involved deciding how many principal components should be. To support the user to possibly make a good decision, we developed a R function called *optimizeCOM*. The idea behind this function was based on random permutations adapted from [32], aimed not only to help the user to know which method should be selected, but also to specify the optimal number of principal components to extract by ICA or IPCA (detailed in Supplementary Method and FigureS2).

Keep components with non-Gaussian distribution

oCEM equipped with ICA and IPCA required the distributions of the signatures across genes must be as non-Gaussian as possible; ideally, they should be heavy-tailed normal distributions. Due to this requirement, the kurtosis was recruited, which statistically describes the “tailedness” of the distribution [22], and only kept signatures whose kurtosis value ≥ 3 .

Detection of co-expressed gene modules

It was evident that a few genes at the tails of a heavy-tailed distribution would be the most important elements in a particular signature, and conversely, the influence of the majority of genes became more and more weak, or even was over, in that signature when they lay at the center of the distribution [22, 23]. Based on this, oCEM provided the users with three optional post-processing steps attached with ICA and IPCA (two for ICA and one for IPCA) to detect co-expressed gene modules.

For the first option of the post-processing step (“ICA-FDR” assigned to the *method* argument of the function *overlapCEM*), oCEM did the extraction of non-Gaussian signatures by ICA (the *fastICA* algorithm was configured using *parallel* extraction method and the default measure of non-Gaussianity *logcosh* approximation of negentropy with $\alpha = 1$), then the *fdrtool* R tool [33] modeled those signatures as a two-distribution mixture (null and alternative). The null (Gaussian) distribution was fitted around the median of the signature distribution. At last, a user-defined probability threshold (e.g., 0.1, 0.01, 0.001, ...), called tail area-based false discovery rate (FDR), was chosen to distribute genes to modules on the condition that a gene whose FDR lesser than the threshold at a signature was assigned to that signature (module). Here we suggested the selection of the sufficiently stringent threshold of 0.001 if appropriate for robustness.

The second option (“ICA-Zscore” assigned to the *method* argument of the function *overlapCEM*) was similar to the first one, but oCEM first did z-score transformation for genes in each signature. A gene belonged to a module if the absolute of its z-score was greater than a user-defined standard deviation threshold (e.g., 0.5σ , 1σ , 1.5σ , ...). We suggested choosing the sufficiently strict threshold of 3σ on either side from the zero mean, which picks only out a few genes in the tails of the distributions, at any time as possible.

The last option (“IPCA-FDR” assigned to the *method* argument of the function *overlapCEM*) was similar to the first one, but here oCEM used IPCA (the *ipca* algorithm was configured using *deflation* extraction method and the default measure of non-Gaussianity *logcosh* approximation of negentropy with $\alpha = 1$) instead of ICA. This algorithm was more robust to noise.

Genes at both extremes of the distribution were considered as hub-genes. The Pearson’s correlations of each resulting co-expressed module to each clinical feature of interest were then calculated and reported in R.

Performance validation of oCEM

Gene expression data

We used two example data, human breast cancer [34] and mouse metabolic syndrome [35], to illustrate the straightforward use of oCEM as well as be convenient for comparing its ability with other tools. In particular, the first case study, downloaded from the cBioPortal for Cancer Genomics (<http://www.cbioportal.org>) [36, 37], was the METABRIC breast cancer cohort in the United Kingdom and Canada. The gene expression data were generated using the Illumina Human v3 microarray for 1,904 samples. The second case study, related to mouse metabolic syndrome (obesity, insulin resistance, and dyslipidemia), was liver gene expressions from 134 female mice including 3600 physiologically relevant genes. The data were employed by the authors of WGCNA [18] to indicate how to use this tool.

Comparison of oCEM with WGCNA and its improved version iWGCNA

We used the two expression data above to validate the performance of oCEM with WGCNA and an improved version of WGCNA proposed by us [38], temporarily called improved WGCNA (iWGCNA) in this study. For WGCNA, we applied it to the gene expression data using the *blockwiseModules* function (v1.69). All tuning parameters were left as default. For iWGCNA, its improvement was that we added an additional step to the gene clustering process, the determination of the optimal cluster agglomeration method for each particular case. All other tuning parameters were set to their default value, except for the selection of the soft-thresholding value [18].

To compare the power of them, we estimated the pairwise Pearson’s correlation coefficients, r , between module eigengenes (MEs, characterized by its first principal component) of resulting modules given by WGCNA (wME) and iWGCNA (iME) versus patterns (i.e., sample components) given by oCEM. This helped us to determine which modules could be missed by WGCNA and iWGCNA. Then, g:Profiler (<https://biit.cs.ut.ee/gprofiler/gost>) (ver *e102_eg49_p15_7a9b4d6*; accessed on 20 Feb. 2021) [39] verified biological processes and KEGG pathways related to those missed modules. Biological processes and KEGG pathways with adjusted P-values ≤ 0.05 (G:SCS multiple testing correction method [39], two-tailed) were considered to be statistically significant.

RESULTS

Human breast cancer

Figure 2. Identification and analysis of functional modules by oCEM. (a) Venn diagram shows the overlap of the 31 driver genes among the three functional modules (oM1, oM2, and oM3). (b) Associations of each module with each of three clinical features of interest. Abbreviation: lymph, the number of lymph nodes; npi, Nottingham prognostic index; stage, tumor stages of all the breast cancer patients; wM, iM, and oM, resulting modules generated by WGCNA, iWGCNA, and oCEM.

In our previous study [38], the breast cancer data were used to detect 31 validated breast-cancer-associated genes, and we then clustered those genes to functional modules using iWGCNA. Here, we revisited the results to be convenient for the comparison. Due to the small number of genes, WGCNA failed to identify any co-expressions across the 1904 breast cancer patients (the 31 genes were in wM0 or called a gray module), while iWGCNA and oCEM indicated two (iM1 and iM2 respective to turquoise and blue modules) and three modules (oM1, oM2, and oM3), respectively. These implied that the ability of iWGCNA and oCEM was better than WGCNA in the co-expressed gene module identification. Figure 2a indicates that oCEM discovered the three co-expressed modules including a corresponding set of genes of which the overlap was allowed. The correlation analyses of the three identified modules were performed automatically by oCEM (Figure 2b). As a result, oM1 showed a significant negative association with the Nottingham prognostic index only. In particular, oM3 was positively significantly correlated with all three clinical features, including the number of lymph nodes, Nottingham prognostic index, and tumor stages of the breast cancer patients. Besides, oCEM also reported the top 10 hub-genes in each of these modules, including *KMT2C*, *BAP1*, *PTEN*, *NF1*, *RUNX1*, *ZFP36L1*, *CDKN1B*, *BRCA2*, *MAP3K1*, and *PIK3CA* in oM1; *CDH1*, *PIK3R1*, *GATA3*, *CDKN2A*, *TBX3*, *SMAD4*, *KRAS*, *RB1*, *MEN1*, and *RUNX1* in oM2; and *KRAS*, *GPS2*, *SF3B1*, *AGTR2*, *RB1*, *NCOR1*, *SMAD4*, *ERBB3*, *FOXO3*, and *NF1* in oM3.

Figure 3. Comparison of identified modules by oCEM with those by WGCNA and iWGCNA. (a) the pairwise Pearson's correlation coefficients were computed between wM0 versus oM1, oM2, and oM3. (b) the pairwise Pearson's correlation coefficients were computed between iM1 and iM2 versus oM1, oM2, and oM3. Abbreviation: wM, iM, and oM, resulting modules generated by WGCNA, iWGCNA, and oCEM.

We further investigated the power of the three methods by estimating the pairwise Pearson's correlation coefficients between the one and two modules given by WGCNA and iWGCNA, respectively, versus the three modules given by oCEM as described in the Material and Methods section above. As expected, one wME (100.0%) and one iME (50.0%) respectively showed $r > 0.4$ with at least one oCEM pattern (i.e., patient components), whereas only 33.3% of oCEM patterns correlated to at least one ME obtained by both WGCNA and iWGCNA with the same intensity (Figure 3a,b and Supplementary TableS1). Collectively, both WGCNA and iWGCNA potentially missed two modules oM2 and oM3 ($r < 0.4$). We functionally enriched the two and realized that they possessed an overlapping set of genes significantly associated with regulation of gene expression and development processes, and biological pathways related to cancer in general and breast cancer in particular (Supplementary TableS2), suggesting that oCEM was most likely to identify biologically relevant modules that were not represented by WGCNA or iWGCNA modules.

Mouse metabolic syndrome

Similarly, we again applied the three tools to 2281 gene expressions in liver of the 134 female mice. As a result, WGCNA, iWGCNA, and oCEM detected 17, 12, and 18 modules, respectively. In this turn, four out of 17 wMEs (23.5%) and four out of 12 iMEs (33.3%) respectively yielded $r > 0.8$ with at least one oCEM pattern (i.e., mouse components). In contrast, those numbers for oCEM were three out of 18 oCEM patterns (16.7%) and four out of 18 oCEM patterns (22.2%) related to at least one wME and one iME with the same intensity, in which WGCNA and iWGCNA could ignore 15 and 14 important oCEM modules ($r < 0.8$), respectively (Supplementary TableS3). We analyzed enrichment on those missed modules, rendering all of them associated significantly with relevant metabolic processes and pathways. More details of the pre-processing procedures, analysis processes, and comparisons were shown in the Supplementary Materials.

DISCUSSION

Co-expressed gene module identification and sample clustering rely mostly on unsupervised clustering methods, resulting in the development of new tools or new analysis frameworks [18, 38, 40, 41]. However, module detection is unique due to necessity of ensuring biological reality in the context of gene expression, such as overlap and local co-expression. In this study, we therefore have presented a new tool, oCEM, for module discovery; especially, it differentiates from other advanced methods on the ability to identify different modules which allow having the overlap between them, better reflecting biological reality than methods that stratify genes into separate subgroups. The fact that oCEM outperforms some state-of-the-art tools, such as WGCNA or iWGCNA, in identifying functional modules of genes. Moreover, oCEM is sufficiently flexible to be applied to any organisms, like human, mouse, yeast, etc. In addition, oCEM is well able to automatically and easily do the two tasks as identification and analysis of modules. These clearly help to support a community of users with diverse backgrounds, such as biologists, bioinformaticians, and bioinformaticists, who are interested in this field.

When using the decomposition methods, the selection of the optimal number of principal components is vital. Here we also introduce *optimizeCOM* that performs a permutation procedure in the hope that the extracted components are generated not-at-random. Based on the two benchmark datasets, including human breast cancer and mouse metabolic syndrome, we can realize that most modules indicated by *optimizeCOM* are highly similar to these indicated by WGCNA and iWGCNA, whereas the rest are new modules significantly associated with clinical features as well as biological processes and pathways. Although further studies are required, these results imply that *optimizeCOM* has the potential to provide a suggestion having high value of reference before using the decomposition methods.

In conclusion, we believe that oCEM tool may be useful, not only to improve module detection, but also to discover novel biological insights in complex diseases.

SOFTWARE AND DATA AVAILABILITY

R package of oCEM and the raw data used in the study are available on GitHub (<https://github.com/huynghuyen250896/oCEM>), respectively. Approval by a local ethics committee was not required, and all the data can be immediately downloaded.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR online.

CONFLICT OF INTEREST

We have no conflicts of interest to disclose.

REFERENCES

1. Eisen, M.B., et al., *Cluster analysis and display of genome-wide expression patterns*. Proceedings of the National Academy of Sciences, 1998. **95**(25): p. 14863-14868.
2. D'haeseleer, P., *How does gene expression clustering work?* Nature biotechnology, 2005. **23**(12): p. 1499-1501.
3. Chaussabel, D. and N. Baldwin, *Democratizing systems immunology with modular transcriptional repertoire analyses*. Nature Reviews Immunology, 2014. **14**(4): p. 271-280.
4. Voineagu, I., et al., *Transcriptomic analysis of autistic brain reveals convergent molecular pathology*. Nature, 2011. **474**(7351): p. 380-384.
5. Jostins, L., et al., *Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease*. Nature, 2012. **491**(7422): p. 119-124.
6. Yosef, N., et al., *Dynamic regulatory network controlling TH 17 cell differentiation*. Nature, 2013. **496**(7446): p. 461-468.
7. Jojic, V., et al., *Identification of transcriptional regulators in the mouse immune system*. Nature immunology, 2013. **14**(6): p. 633-643.
8. Paul, F., et al., *Erratum: Transcriptional Heterogeneity and Lineage Commitment in Myeloid Progenitors (Cell (2015) 163 (1663-1677))*. Cell, 2016. **164**(1-2).
9. Alsina, L., et al., *A narrow repertoire of transcriptional modules responsive to pyogenic bacteria is impaired in patients carrying loss-of-function mutations in MYD88 or IRAK4*. Nature immunology, 2014. **15**(12): p. 1134-1142.
10. Chaussabel, D., et al., *A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus*. Immunity, 2008. **29**(1): p. 150-164.
11. Arnone, M.I. and E.H. Davidson, *The hardwiring of development: organization and function of genomic regulatory systems*. Development, 1997. **124**(10): p. 1851-64.
12. Miklos, G.L. and G.M. Rubin, *The role of the genome project in determining gene function: insights from model organisms*. Cell, 1996. **86**(4): p. 521-9.
13. Neph, S., et al., *Circuitry and dynamics of human transcription factor regulatory networks*. Cell, 2012. **150**(6): p. 1274-1286.
14. Marbach, D., et al., *Wisdom of crowds for robust gene network inference*. Nature methods, 2012. **9**(8): p. 796-804.
15. Rotival, M., et al., *Integrating genome-wide genetic variations and monocyte expression data reveals trans-regulated gene modules in humans*. PLoS Genet, 2011. **7**(12): p. e1002367.
16. Eren, K., et al., *A comparative analysis of biclustering algorithms for gene expression data*. Briefings in bioinformatics, 2013. **14**(3): p. 279-292.
17. Roy, S., et al., *Integrated module and gene-specific regulatory inference implicates upstream signaling networks*. PLoS Comput Biol, 2013. **9**(10): p. e1003252.
18. Langfelder, P. and S. Horvath, *WGCNA: an R package for weighted correlation network analysis*. BMC Bioinformatics, 2008. **9**(1): p. 559.
19. Lance, G.N. and W.T. Williams, *A General Theory of Classificatory Sorting Strategies: 1. Hierarchical Systems*. The Computer Journal, 1967. **9**(4): p. 373-380.
20. Saelens, W., R. Cannoodt, and Y. Saeys, *A comprehensive evaluation of module detection methods for gene expression data*. Nature Communications, 2018. **9**(1): p. 1090.
21. Comon, P., *Independent component analysis, a new concept?* Signal processing, 1994. **36**(3): p. 287-314.
22. Hyvärinen, A. and E. Oja, *Independent component analysis: algorithms and applications*. Neural networks, 2000. **13**(4-5): p. 411-430.
23. Liebermeister, W., *Linear modes of gene expression determined by independent component analysis*. Bioinformatics, 2002. **18**(1): p. 51-60.
24. Jolliffe, I.T. and J. Cadima, *Principal component analysis: a review and recent developments*. Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences, 2016. **374**(2065): p. 20150202.
25. Yao, F., J. Coquery, and K.-A. Lê Cao, *Independent Principal Component Analysis for biologically meaningful dimension reduction of large biological data sets*. BMC Bioinformatics, 2012. **13**(1): p. 24.

26. Lee, S.-I. and S. Batzoglou, *Application of independent component analysis to microarrays*. Genome biology, 2003. **4**(11): p. 1-21.
27. Purdom, E. and S.P. Holmes, *Error distribution for gene expression data*. Statistical applications in genetics and molecular biology, 2005. **4**(1).
28. Huang, D.-S. and C.-H. Zheng, *Independent component analysis-based penalized discriminant method for tumor classification using gene expression data*. Bioinformatics, 2006. **22**(15): p. 1855-1862.
29. Engreitz, J.M., et al., *Independent component analysis: mining microarray data for fundamental human gene expression modules*. Journal of biomedical informatics, 2010. **43**(6): p. 932-944.
30. Scholz, M., et al., *Metabolite fingerprinting: detecting biological features by independent component analysis*. Bioinformatics, 2004. **20**(15): p. 2447-2454.
31. Yeung, K.Y. and W.L. Ruzzo, *Principal component analysis for clustering gene expression data*. Bioinformatics, 2001. **17**(9): p. 763-774.
32. Horn, J.L., *A rationale and test for the number of factors in factor analysis*. Psychometrika, 1965. **30**(2): p. 179-185.
33. Strimmer, K., *A unified approach to false discovery rate estimation*. BMC bioinformatics, 2008. **9**(1): p. 1-14.
34. Pereira, B., et al., *The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes*. Nature Communications, 2016. **7**(1): p. 11479.
35. Ghazalpour, A., et al., *Integrating Genetic and Network Analysis to Characterize Genes Related to Mouse Weight*. PLOS Genetics, 2006. **2**(8): p. e130.
36. Cerami, E., et al., *The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data*. Cancer Discovery, 2012. **2**(5): p. 401-404.
37. Gao, J., et al., *Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal*. Sci Signal, 2013. **6**(269): p. p11.
38. Nguyen, Q.-H. and D.-H. Le, *Improving existing analysis pipeline to identify and analyze cancer driver genes using multi-omics data*. Scientific Reports, 2020. **10**(1): p. 20521.
39. Raudvere, U., et al., *g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update)*. Nucleic Acids Research, 2019. **47**(W1): p. W191-W198.
40. Nguyen, Q.-H., et al., *Multi-omics analysis detects novel prognostic subgroups of breast cancer*. Frontiers in Genetics, 2020.
41. Nguyen, H., et al. *Disease subtyping using community detection from consensus networks*. in 2020 12th International Conference on Knowledge and Systems Engineering (KSE). 2020.

FIGURES LEGENDS

Figure 1. Automatic analysis framework of oCEM. Gene expression data first underwent the two pre-processing steps: removal of outlier samples and normalization. Then, the user could refer to the recommendation of oCEM regarding which decomposition method should be selected and how many component numbers were optimal by using the function *optimizeCOM*. Next, the processed data were inputted into the function *overlapCEM*, rendering co-expressed gene modules (i.e., Signatures with their own kurtosis ≥ 3) and Patterns. Kurtosis statistically describes the “tailedness” of the distribution relative to a normal distribution. Finally, corresponding hub-genes in each module and the association between each module and each clinical feature of choice were identified.

Figure 2. Identification and analysis of functional modules by oCEM. (a) Venn diagram shows the overlap of the 31 driver genes among the three functional modules (oM1, oM2, and oM3). (b) Associations of each module with each of three clinical features of interest. Abbreviation: lymph, the number of lymph nodes; np, Nottingham prognostic index; stage, tumor stages of all the breast cancer patients; wM, iM, and oM, resulting modules generated by WGCNA, iWGCNA, and oCEM.

Figure 3. Comparison of identified modules by oCEM with those by WGCNA and iWGCNA. (a) the pairwise Pearson’s correlation coefficients were computed between wM0 versus oM1, oM2, and oM3. (b) the pairwise Pearson’s correlation coefficients were computed between iM1 and iM2 versus oM1, oM2, and oM3. Abbreviation: wM, iM, and oM, resulting modules generated by WGCNA, iWGCNA, and oCEM.